Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report)’s share price traded down 6.7% during mid-day trading on Wednesday . Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. Relay Therapeutics Company Profile(Get Free Report)Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Featured StoriesReceive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.